Considerations for In Vitro Nanotoxicity Testing

Handbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology

Volumn , Issue , 2014, Pages 35-64

  Keene, Athena M ^a   Bancos, Simona ^b   Tyner, Katherine M ^b  

^a AFTON CHEMICAL CORPORATION   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Assay interference; Cytotoxicity; in vitro; Nanoparticle; Nanotoxicity

Indexed keywords

CYTOTOXICITY; NANOPARTICLES;

EXPERIMENTAL CONDITIONS; HIGH THROUGHPUT; IN-VITRO; IN-VITRO ASSAYS; IN-VIVO; NANOTOXICITY;

ASSAYS;

EID: 84940867407     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118856017.ch2     Document Type: Chapter

References (113)

1. Aggarwal P, Dobrovolskaia M. 2011. Gold nanoparticle quantitation via fluorescence solution and cell culture. In Characterization of Nanoparticles Intended for Drug Delivery. Methods in Molecular Biology, Vol. 697, McNeil SE (ed)., pp. 137-143. doi: 10.1007/978-1-60327-198-1_14.
2. Ahmad J, Ahamed M, Akhtar MJ, Alrokayan SA, Siddiqui MA, Musarrat J, Abdulaziz A, Al-Khedhairy AA. 2012. Apoptosis induction by silica nanoparticles mediated through reactive oxygen species in human liver cell line HepG2. Toxicol. Appl. Pharmaco. 259: 160-168. doi:10.1016/j.taap.2011.12.020.
3. Anton N, Benoit JP, Saulnier P. 2008. Design and production of nanoparticles formulated from nano-emulsion templates - a review. J. Control. Release 128: 185-199. doi:10.1016/j.jconrel.2008.02.007.
4. Auffan M, Rose J, Bottero JY, Lowry GV, Jolivet JP, Wiesner MR. 2009. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat. Nanotechnol. 4: 634-641. doi:10.1038/nnano.2009.242.
5. Bakand S, Winder C, Khalil C, Hayes A. 2005. Toxicity assessment of industrial chemicals and airborne contaminants: transition from in vivo to in vitro test methods: a review. Inhal. Toxicol. 17: 775-787. doi:10.1080/08958370500225240.
6. Belyanskaya L, Manser P, Spohn P, Bruinink A, Wick P. 2007. The reliability and limits of the MTT reduction assay for carbon nanotubes-cell interaction. Carbon 45: 2643-2648. doi:10.1016/j.carbon.2007.08.010.
7. Berg JM, Ho S, Hwang W, Zebda R, Cummins K, Soriaga MP, Taylor R, Guo B, Sayes CM. 2010. Internalization of carbon black and maghemite iron oxide nanoparticle mixtures leads to oxidant production. Chem. Res. Toxicol. 23: 1874-1882. doi:10.1021/tx100307h.
8. Bernas T, Dobrucki J. 2002. Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 47: 236-242. doi:10.1002/cyto.10080.
9. Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC. 2005. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol. Sci. 88: 412-419. doi:10.1093/toxsci/kfi256.
10. Brown DM, Dickson C, Duncan P, Al-Attili F, Stone V. 2010. Interactions between nanoparticles and cytokine proteins; impact on protein and particle functionality. Nanotechnology 12: 215104. doi:10.1088/0957-4484/21/21/215104.
11. Burt SM, Carter TJ, Kricka LJ. 1979. Thermal characteristics of microtitre plates used in immunological assays. J. Immunol. Methods 31: 231-236. doi:10.1016/0022-1759(79)90135-2.
12. Buttke TM, McCubrey JA, Owen TC. 1993. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods 157(1-2): 233-240. doi:10.1016/0022-1759(93)90092-L.
13. Cao XG, Li XX, Bao YZ, Xing NZ, Chen Y. 2007. Responses of human lens epithelial cells to quercetin and DMSO. Invest. Ophthalmol. Vis. Sci. 48: 3714-3718. doi:10.1167/iovs.06-1304.
14. Casey A, Davoren M, Herzog E, Lyng FM, Byrne HJ, Chambers G. 2007a. Probing the interaction of single walled carbon nanotubes within cell culture medium as a precursor to toxicity testing. Carbon 45: 34-40. doi:10.1016/j.carbon.2006.08.009.
15. Casey A, Herzog E, Lyng FM, Byrne HJ, Chambers G. 2007b. Spectroscopic analysis confirms the interactions between single walled carbon nanotubes and various dyes commonly used to assess cytotoxicity. Carbon 45: 1425-1432. doi:10.1016/j.carbon.2007.03.0.
16. Casey A, Herzog E, Lyng FM, Byrne HJ, Chambers G, Davoren M. 2008. Single walled carbon nanotubes induce indirect cytotoxicity by medium depletion in A549 lung cells. Toxicol. Lett. 179(2): 78-84. doi:10.1016/j.toxlet.2008.04.006.
17. Caux PY, Blaise C, LeBlanc P, Tache M. 1992. A phytoassay procedure using fluorescence induction. Environ. Toxicol. Chem. 11: 549-557. doi:10.1897/1552-8618(1992)11[549:APPUFI]2.0.CO;2.
18. Chithrani BD, Arezou A, Ghazani AA, Chan WCW. 2006. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6: 662-668. doi:10.1021/nl052396o.
19. Cho WS, Cho MJ, Jeong J, Choi M, Cho HY, Han BS, Kim SH, Kim HO, Lim TY, Chung BH, Jeong J. 2009. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharm. 236: 16-24. doi:10.1016/j.taap.2008.12.023.
20. Cho EC, Zhang Q, Xia Y. 2011. The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat. Nanotech. 6: 385-391. doi:10.1038/nnano.2011.58.
21. Christian P, Von der KF, Baalousha M, Hofmann T. 2008. Nanoparticles: structure, properties, preparation and behaviour in environmental media. Ecotoxicology 17: 326-343. doi:10.1007/s10646-008-0213-1.
22. Chua A, Yean CY, Ravichandran M, Lim B, Lalitha P. 2011. A rapid DNA biosensor for the molecular diagnosis of infectious disease. Biosens. Bioelectron. 26: 3825-3831. doi:10.1016/j.bios.2011.02.040.
23. Clift MJ, Rothen-Rutishauser B, Brown DM, Duffin R, Donaldson K, Proudfoot L, Guy K, Stone V. 2008. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol. Appl. Pharmacol. 232: 418-427. doi:10.1016/j.taap.2008.06.009.
24. Collins FS, Gray GM, Bucher JR. 2008. Toxicology. Transforming environmental health protection. Science 319: 906-907. doi:10.1126/science.1154619.
25. Datar RH, Cote RJ. 2010. Nanomedicine: concepts, status, and the future. Med. Innov. Bus. 2: 6-17.
26. Davoren M, Herzog E, Casey A, Cottineau B, Chambers G, Byrne HJ, Lyng FM. 2007. In vitro toxicity evaluation of singlewalled carbon nanotubes on human A549 lung cells. Toxicol. In Vitro 21: 438-448. doi:10.1016/j.tiv.2006.10.0.
27. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJAM, Geertsma RE. 2008. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29: 1912-1919. doi:10.1016/j.biomaterials.2007.12.037.
28. Derfus AM, Chan WCW, Bhatia SN. 2004. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 4: 11-18. doi:10.1021/nl03473.
29. Doak SH, Griffiths SM, Manshian B, Singh N, Williams PM, Brown AP, Jenkins GJS. 2009. Confounding experimental considerations in nanogenotoxicology. Mutagenisis 24: 285-293. doi:10.1093/mutage/gep010.
30. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. 2008a. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5: 487-495. doi:10.1021/mp800032f.
31. Dobrovolskaia MA, Clogston JD, Neun BW, Hall JB, Patri AK, McNeil SE. 2008b. Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 8: 2180-2187. doi:10.1021/nl080561.
32. Dobrovolskaia MA, Germolec DR, Weaver JL. 2009. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4: 411-414. doi:10.1038/NNANO.2009.175.
33. Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE. 2010. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine 5: 555-562. doi:10.2217/NNM.10.29.
34. Donaldson K, Poland CA, Schins RP. 2010. Possible genotoxic mechanisms of nanoparticles: criteria for improved test strategies. Nanotoxicology 4: 414-420. doi:10.3109/17435390.2010.482751.
35. Fadeel B, Garcia-Bennett AE. 2010. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv. Drug Deliv. Rev. 62: 362-374. doi:10.1016/j.addr.2009.11.008.
36. Falck GCM, Lindberg HK, Suhonen S, Vippola M, Vanhala E, Catalan J, Savolainen K, Norppa H. 2009. Genotoxic effects of nanosized and fine TiO2. Hum. Exp. Toxicol. 28(6-74): 339-352. doi:10.1177/0960327109105163.
37. Farokhzad OC, Langer R. 2009. Impact of nanotechnology on drug delivery. ACS Nano 3: 16-20. doi:10.1021/nn900002m.
38. Fisichella M, Dabboue H, Bhattacharyya S, Saboungi ML, Salvetat JP, Hevor T, Guerin M. 2009. Mesoporous silica nanoparticles enhance MTT formazan exocytosis in HeLa cells and astrocytes. Toxicol. In Vitro 23: 697-703. doi:10.1016/j.tiv.2009.02.007.
39. Freshney RI. 2005. Culture of Animal Cells, a Anual of Basic Technique. John Wiley and Sons, Inc.: New Jersey.
40. Gerloff K, Albrecht C, Boots AW, Forster I, Schins RPF. 2009. Cytotoxicity and oxidative damage by nanopartiacles in human intestinal Caco-2 cells. Nanotoxicology 3(4): 355-364. doi:10.3109/17435390903276933.
41. Gerloff K, Pereira DIA, Nuno Faria N, Boots AW, Kolling J, Förster I, Albrecht C, Powell JJ, Roel PF, Schins RPF. 2012. Influence of simulated gastrointestinal conditions on particle-induced cytotoxicity and interleukin-8 regulation in differentiated and undifferentiated Caco-2 cells. Nanotoxicology. doi:10.3109/17435390.2012.662249.
42. Guo L, Von Dem BA, Buechner M, Yan A, Kane AB, Hurt RH. 2008. Adsorption of essential micronutrients by carbon nanotubes and the implications for nanotoxicity testing. Small 4: 721-727. doi:10.1002/smll.200700754.
43. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. 2007. Characterization of nanoparticles for therapeutics. Nanomedicine 2: 789-803. doi:10.2217/17435889.2.6.789.
44. Han X, Gelein R, Corson N, Wade-Mercer P, Jiang J, Biswas P, Finkelstein JN, Elder A, Oberdorster G. 2011. Validation of an LDH assay for assessing nanoparticle toxicity. Toxicology 287: 99-104. doi:10.1016/j.tox.2011.06.011.
45. Han X, Corson N, Wade-Mercer P, Gelein R, Jiang J, Sahu M, Biswas P, Finkelstein JN, Elder A, Oberdörster G. 2012. Assessing the relevance of in vitro studies in nanotoxicology by examining correlations between in vitro and in vivo data. Toxicology 16: 1-9. doi:10.1016/j.tox.2012.03.006.
46. Handy RD, van den Brink N, Chappell M, Muhling M, Behra R, Dusinska M, Simpson P, Ahitiainen J, Jha AN, Seiter J, Bednar A, Kennedy A, Fernandes TF, Riediker M. 2012. Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far? Ecotoxicology 21: 933-972. doi:10.1007/s10646-012-0862-y.
47. Hinderliter PM, Minard KR, Orr G, Chrisler WB, Thrall BD, Pounds JG, Teeguarden JG. 2010. ISDD: A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part. Fibre Toxicol. 7: 36. doi:10.1186/1743-8977-7-36.
48. Holder AL, Goth-Goldstein R, Lucas D, Koshland CP. 2012. Particle-induced artifacts in theMTTand LDH viability assays. Chem. Res. Toxicol. 25: 1885-1892. doi:10.1021/tx3001708.
49. Horie M, Kato H, Fugita K, Fujita K, Endo S, Iwahashi H. 2012. In vitro evaluation of cellular response induced by manufactured nanoparticles. Chem. Res. Toxicol. 25: 605-619.
50. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ. 2005. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol. In Vitro 19: 975-983. doi:10.1021/tx200470e.
51. Ispas C, Andreescu D, Patel A, Goia DV, Andreescu S, Wallace KN. 2009. Toxicity and developmental defects of different sizes and shape nickel nanoparticles in zebrafish. Environ. Sci. Technol. 43: 6349-6356. doi:10.1021/es9010543.
52. Jones C, Grainger DW. 2008. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61: 438-456. doi:10.1016/j.addr.2009.03.005.
53. Karlsson HL. 2010. The comet assay in nanotoxicology research. Anal. Bioanal. Chem. 398: 651-666. doi:10.1007/s00216-010-3977-0.
54. Keene AM, Tyner KM. 2011. Analytical characterization of gold nanoparticle primary particles, aggregates, agglomerates, and agglomerated aggregates. J. Nanopart. Res. 13: 3465-3481. doi:10.1007/s1a1051-011-0268-4.
55. Keene AM, Balasubramanian R, Lloyd J, Shainberg A, Jacobson KA. 2010. Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor. Biochem. Pharmacol. 80: 188-196. doi:10.1016/j.bcp.2010.03.020.
56. Keene AM, Allaway R, Sadrieh N, Tyner KM. 2011. Gold nanoparticle trafficking of typically excluded compounds across the cell membrane causes assay interference. Nanotoxicology 5: 469-478. doi:10.3109/17435390.2010.533792.
57. Keene AM, Peters D, Rouse R, Stewart S, Rosen ET, Tyner KM. 2012. Tissue and cellular distribution of gold nanoparticles varies based on aggregation/agglomeration status. Nanomedicine 7: 199-209. doi:10.2217/NNM.11.125.
58. Kim JA, Aberg C, Salvati A, Dawson KA. 2011. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nature Nanotech. 7: 62-68. doi:10.1038/nnano.2011.191.
59. Kocbach A, Totlandsdal AI, Lag M, Refsnes M, Schwarze PE. 2008. Differential binding of cytoknies to environementally relvant particles: a possible source for misinterpretation of in vivo results? Toxicol. Lett. 176: 131-137. doi:10.1016/j.toxlet.2007.10.014.
60. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. 2009. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur. J. Pharm. Biopharm. 72: 370-377. doi:10.1016/j.ejpb.2008.08.009.
61. Kroll A, Dierker C, Rommel C, Hahn D, Wohlleben W, Schulze-Isfort C, Gobbert C, Voetz M, Hardinghaus F, Schnekenburger J. 2011. Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays. Part. Fibre Toxicol. 8: 9. doi:10.1186/1743-8977-8-9.
62. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. 2012. Interference of engineered nanoparticles with in vitro toxicity assays. Arch. Toxicol. 86: 1123-1136. doi:10.1007/s00204-012-0837-z.
63. L'Azou B, Jorly J, On D, Sellier E, Moisan F, Fleury-Feith J, Cambar J, Brochard P, Ohayon-Courtes C. 2008. In vitro effects of nanoparticles on renal cells. Part. Fibre Toxicol. 5: 22. doi:10.1186/1743-8977-5-22.
64. Laaksonen T, Santos H, Vihola H, Salonen J, Riikonen J, Heikkila T, Peltonen L, Kumar N, Murzin DY, Lehto VP, Hirvonen J. 2007. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem. Res. Toxicol. 20: 1913-1918. doi:10.1021/tx700326b.
65. Lam CW, James JT, McCluskey R, Arepalli S, Hunter RL. 2006. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol. 36: 189-217. doi:10.1080/10408440600570233.
66. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA, Olmedo I, Clos A, Ramanujam VMS, Urayama A, Vergara L, Kogan MJ, Soto C. 2010. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Bioph. Res. Co. 393: 649-655. doi:10.1016/j.bbrc.2010.02.046.
67. Lemasters JJ. 2010. Cytolethality. In Comprehensive Toxicology, 2nd edn, McQueen C (ed). Elsevier: Oxford, UK.
68. Lewinski N, Colvin V, Drezek R. 2008. Cytotoxicity of nanoparticles. Small 4: 26-49. doi:10.1002/smll.200700595.
69. Lin MH, Hsu TS, Yang PM, Tsai MY, Perng TP, Lin LY. 2009. Comparison of organic and inorganic germanium compounds in cellular radiosensitivity and preparation of germanium nanoparticles as a radiosensitizer. Int. J. Radiat. Biol. 85(3): 214-226. doi:10.1080/09553000902748583.
70. Lindberg HK, Falck GCM, Suhonen S, Vippola M, Vanhala E, Catalan J, Savolainen K, Norppa H. 2008. Genotoxicity of nanomaterials: DNA damage and micronuclei induced by carbon nanotubes and graphite nanofibres in human bronchial epithelial cells in vitro. Toxicol. Lett. 186(3): 166-173. doi:10.1016/j.toxlet.2008.11.019.
71. Low SP, Williams KA, Canham LT, Voelcker NH. 2006. Evaluation of mammalian cell adhesion on surface-modified porous silicon. Biomaterials 27: 4538-4546. doi:10.1016/j.biomaterials.2006.04.015.
72. Lunov O, Syrovets T, Loos C, Beil J, Delacher M, Tron K, Nienhaus GU, Musyanovych A, Maileander V, Landfester K, Simmet T. 2011. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 5(3): 1657-1669. doi:10.1021/nn2000756.
73. Magdolenova Z, Lorenzo Y, Collins A, Dusinska M. 2012. Can standard genotoxicity tests be applied to nanoparticles? J. Toxicol. Environ. Health A 75: 800-806. doi:10.1080/15287394.2012.690326.
74. Mahmoudi M, Simchi A, Imani M, Shokrgozar MA, Milani AS, Hafeli UO, Stroeve P. 2010. A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloid. Surf. B. 75: 300-309. doi:10.1016/j.colsurfb.2009.08.044.
75. Malugin A, Ghandehari H. 2010. Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J. Appl. Toxicol. 30(3): 212-217. doi:10.1002/jat.1486.
76. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3): 165-196.
77. Monteiro-Riviere NA, Inman AO. 2006. Challenges for assessing carbon nanomaterial toxicity to the skin. Carbon 44: 1070-1078. doi:10.1016/j.carbon.2005.11.004.
78. Monteiro-Riviere NA, Inman AO, Zhang LW. 2009. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 234(2): 222-235. doi:10.1016/j.taap.2008.09.03.
79. Mortimer M, Kasemets K, Heinlaan M, Kurvet I, Kahru A. 2008. High throughput kinetic Vibrio fischeri bioluminescence inhibition assay for study of toxic effects of nanoparticles. Toxicol. In Vitro 22(5): 1412-1417. doi:10.1016/j.tiv.2008.02.011.
80. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1-2): 55-63. doi:10.1016/0022-1759(83)90303-4.
81. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. 1997. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14(4): 458-462. doi:10.1023/A:1012043315093.
82. Murthy RSR, Pathak Y. 2009. In vitro blood interaction and pharmacological and toxicological characterization of nanosystems. In Drug Delivery Nanoparticles Formulation and Characterization, Pathak Y, Thassu D (eds). Informa Healthcare: New York.
83. National Science and Technology Council Committee on Technology Subcommittee on Nanoscale Science (2011) National Nanotechnology Initiative Strategic Plan, www.nano.gov [09 November 2013].
84. Nel A, Xia T, Madler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science 311(5761): 622-627. doi:10.1126/science.1114397.
85. Nitin N, Javier DJ, Richards-Kortum R. 2007. Oligonucleotidecoated metallic nanoparticles as a flexible platform for molecular imaging agents. Bioconjug. Chem. 18(6): 2090-2096. doi:10.1021/bc0701242.
86. Niyogi S, Boukhalfa S, Chikkannanavar SB, McDonald TJ, Heben MJ, Doorn SK. 2007. Selective aggregation of single-walled carbon nanotubes via salt addition. J. Am. Chem. Soc. 129(7): 1898-1899. doi:10.1021/ja068321j.
87. Oostingh GJ, Casals E, Italiani P, Colognato R, Stritzinger R, Ponti J, Pfaller T, Kohl Y, Ooms D, Favilli F, Leppens H, Lucchesi D, Rossi F, Nelissen I, Thielecke H, Puntes VF, Duschl A, Boraschi D. 2011. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part. Fibre Toxicol. 8(1): 8. doi:10.1186/1743-8977-8-8.
88. Park MVDZ, Lankveld DPK, van Loveren H, de Jong WH. 2009. The status of in vitro toxicity studies in the risk assessment of nanomaterials. Nanomedicine 4(6): 669-685. doi:10.2217/NMM.09.40.
89. Parvez S, Venkataraman C, Mukherji S. 2006. A review on advantages of implementing luminescence inhibition test (Vibrio fischeri) for acute toxicity prediction of chemicals. Environ. Int. 32(2): 265-268. doi:10.1016/j.envint.2005.08.022.
90. Petushkov A, Intra J, Graham JB, Larsen SC, Salem AK. 2009. Effect of crystal size and surface functionalization on the cytotoxicity of silicalite-1 nanoparticles. Chem. Res. Toxicol. 22(7): 1359-1368. doi:10.1021/tx900153k.
91. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, Leppens H, Ponti J, Stritzinger R, Puntes V, Boraschi D, Duschl A, Oostingh GJ. 2010. The suitability of different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events. Nanotoxicology 4(1): 52-72. doi:10.3109/17435390903374001.
92. Pujalte T, Passagne I, Brouillaud B, Treguer M, Durand E, Courtes CO, L'Azou B. 2011. Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells. Part. Fibre Toxicol. 8: 10. doi:10.1186/1743-8977-8-10.
93. Rivera GP, Oberdorster G, Elder A, Puntes V, Parak WJ. 2010. Correlating physico-chemical with toxicological properties of nanoparticles: the present and the future. ACS Nano 4(10): 5527-5531. doi:10.1021/nn1025687.
94. Rogers EJ, Hsieh SF, Organti N, Schmidt D, Bello D. 2008. A high throughput in vitro analytical approach to screen for oxidative stress potential exerted by nanomaterials using a biologically relevant matrix: human blood serum. Toxicol. In Vitro 22(6): 1639-1647. doi:10.1016/j.tiv.2008.06.001.
95. Rout L, Jammi S, Punniyamurthy T. 2007. Novel CuO nanoparticle catalyzed C-N cross coupling of amines with iodobenzene. Org. Lett. 9(17): 3397-3399. doi:10.1021/ol0713887.
96. Sayes CM, Warheit DB. 2009. Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(6): 660-670. doi:10.1002/wnan.58.
97. Seagrave J, Knall C, McDonald JD, Mauderly JL. 2004. Diesel particulate material binds and concentrates a proinflammatory cytokine that causes neutrophil migration. Inhal. Toxicol. 16: 93-98. doi:10.1080/08958370490443178.
98. Service RF. 2005. Nanotechnology. Calls rise for more research on toxicology of nanomaterials. Science 310(5754): 1609. doi:10.1126/science.310.5754.1609.
99. Spohn P, Hirsch C, Hasler F, Bruinink A, Krug HF, Wick P. 2009. C60 fullerene: a powerful antioxidant or a damaging agent? The importance of an in-depth material characterization prior to toxicity assays. Environ. Pollut. 157(4): 1134-1139. doi:10.1016/j.envpol.2008.08.013.
100. Stone V, Johnston H, Schins RP. 2009. Development of in vitro systems for nanotoxicology: methodological considerations. Crit. Rev. Toxicol. 39(7): 613-626. doi:10.1080/10408440903120975.
101. Suska F, Gretzer C, Esposito M, Tengvall P, Thomsen P. 2005. Monocyte viability on titanium and copper coated titanium. Biomaterials 26(30): 5942-5950. doi:10.1016/j.biomaterials.2005.03.017.
102. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. 2007. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 95(2): 300-312. doi:10.1093/toxsci/kfl165.
103. Tinkle SS. 2010. Maximizing safe design of engineered nanomaterials: the NIH and NIEHS research perspective. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2(1): 88-98. doi:10.1002/wnan.63.
104. USFDA (2011) Considerations Whether an FDA-Regulated Product Invovles the Application of Nanotechonology. Guidance for Industry, Draft Guidance, www.fda.gov [09 November 2013].
105. Val S, Hussain S, Boland S, Hamel R, Baeza-Squiban A, Marano F. 2009. Carbon black and titanium dioxide nanoparticles induce pro-inflammatory responses in bronchial epithelial cells: need for multiparametric evaluation due to adsorption artifacts. Inhal. Toxicol. 21(S1): 115-1220. doi:10.1080/08958370902942533.
106. Veranth JM, Kaser EG, Veranth MM, Koch M, Yost GS. 2007. Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared to soil dust. Part. Fibre Toxicol. 4(2). doi:10.1186/1743-8977-4-2.
107. Wahl B, Daum N, Ohrem HL, Lehr CM. 2008. Novel luminescence assay offers new possibilities for the risk assessment of silica nanoparticles. Nanotoxicology 2(4): 243-251. doi:10.1080/17435390802513204.
108. Warheit DB. 2008. How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization? Toxicol. Sci. 101(2): 183-185. doi:10.1093/toxsci/kfm279.
109. Waters KM, Masiello LM, Zangar RC, Tarasevich BJ, Karin NJ, Quesenberry RD, Bandyopadhyay S, Teeguarden JG, Pound JG, Thrall BD. 2009. Macrophage responses to silica nanoparticles are highly conserved across particle sizes. Toxicol. Sci. 107(2): 553-569. doi:10.1093/toxsci/kfn250.
110. Worle-Knirsch JM, Pulskamp K, Krug HF. 2006. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett. 6(6): 1261-1268. doi:10.1021/nl060177c.
111. Yin JJ, Liu J, Ehrenshaft M, Roberts JE, Fu PP, Mason RP, Zhao B. 2012. Phototoxicity of nano titanium dioxides in HaCaT keratinocytes-generation of reactive oxygen species and cell damage. Toxicol. Appl. Pharmacol. 263: 81-88. doi:10.1016/j.taap.2012.06.001.
112. Ying E, Hwang HM. 2010. In vitro evaluation of the cytotoxicity of iron oxide nanoparticles with different coatings and different sizes in A3 human T lymphocytes. Sci. Total Environ. 408(20): 4475-4481. doi:10.1016/j.scitotenv.2010.07.02.
113. Zhu ZJ, Ghosh PS, Miranda OR, Vachet RW, Rotello VM. 2008. Multiplex screening of cellular uptake of gold nanoparticles using laser desoprtion/ionization mass spectrometry. J. Am. Chem. Soc. 130(43): 14139-14143. doi:10.1021/ja805392f.